Healthcare Industry News: arrhythmia
News Release - May 5, 2011
Endosense and BIOTRONIK Mark 1,000th Procedure Performed with the TactiCath(R) Force-Sensing Ablation Catheter
GENEVA & BERLIN--(Healthcare Sales & Marketing Network)-- Endosense and BIOTRONIK SE & Co. KG have announced that Endosense’s TactiCath1 contact-force sensing ablation catheter has been used to perform more than one thousand patient cases of atrial fibrillation (AF) in Europe within the last twelve months. The commercial milestone, which coincided with the companies’ presence at the Heart Rhythm Society’s 32nd Annual Scientific Sessions in San Francisco, marks a significant achievement for both organizations. Endosense pioneered the field of contact-force sensing in catheter ablation with the development of its TactiCath catheter and accompanying Tactisys system, the second generation of which were launched in April 2010. BIOTRONIK has built and is continuing to grow the market for the TactiCath as its exclusive distributor in Europe as well as Latin America, Canada, Africa and the Middle East.“The one thousandth patient case is a major landmark for both Endosense and BIOTRONIK, as it is a tangible metric indicating how well and how quickly our novel contact-force sensing technology is being embraced by the electrophysiology community,” said Eric Le Royer, chief executive officer, Endosense. “These achievements are a testament to our solid working partnership and to the value of contact-force sensing for electrophysiologists.”
The TactiCath’s commercial success is supported by a continuously growing body of evidence that reinforces the value of force sensing in improving patient outcomes of catheter ablation procedures. Endosense is building upon this data with a range of post-market studies as well as the TOCCASTAR investigational device exemption (IDE) clinical trial, which commenced in January 2011 and is rapidly enrolling patients. The company intends to greatly expand access to contact-force sensing in the electrophysiology lab with an open platform strategy to integrate its technology into a range of 3D mapping systems.
About BIOTRONIK SE & Co. KG
As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of over 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.
About Endosense
Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Launched in April 2010 with a full release in September 2010, the second generation of the novel device has been used across Europe to treat more than one thousand patient cases of atrial fibrillation (AF) and supraventricular tachycardia (SVT). Endosense is currently conducting several post-market clinical studies aimed at proving the superiority of the TactiCath force-sensing catheter over standard irrigated catheters, as well as the TOCCASTAR investigational device exemption (IDE) clinical trial. The company is also executing an open platform strategy to integrate its technology into a range of three-dimensional cardiac mapping systems. BIOTRONIK is the exclusive distributor of the TactiCath in Europe, Latin America, Canada, Africa and the Middle East.
Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit www.endosense.com.
1 Caution: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.
Source: Endosense
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
